Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: A retrospective study

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1695-1700

  Caballero, Joshua ^a,b   Hitchcock, Michael ^a   Scharre, Douglas ^a   Beversdorf, David ^a   Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; atypical antipsychotics; cognition; quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE;

ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BIOASSAY; COGNITION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; OUTPATIENT; PSYCHOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; COMORBIDITY; FEMALE; HUMANS; MALE; MENTAL DISORDERS; RETROSPECTIVE STUDIES;

EID: 33751539763     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.008     Document Type: Article

References (24)

1. Hebert L.E., Scherr P.A., Bienias J.L., et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60 (2003) 1119-1122
2. Wragg R.E., and Jeste D.V. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 146 (1989) 577-587
3. Finkel S.I., Costa Silva J., Cohen G., et al. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8 Suppl 3 (1996) 497-500
4. Suh G.H., and Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: A 1 -year prospective study in a nursing home. Int Psychogeriatr 17 (2005) 429-441
5. Liperoti R., Gambassi G., Lapane K.L., et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 66 (2005) 1090-1096
6. Wei Z., Mousseau D.D., Richardson J.S., et al. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid (25-35) by modulating Bax and BclX(Ils) expression and localization. J Neurosci Res 74 (2003) 942-947
7. Qing H., Xu H., Wei Z., et al. The abiliry of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 17 (2003) 1563-1570
8. Katz I.R., Jeste D.V., Mintzer J.E., et al., Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, doubleblind trial. J Clin Psychiatry 60 (1999) 107-115
9. De Deyn P.P., Rabheru K., Rasmussen A., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 946-955
10. Brodaty H., Ames D., Snowdon J., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64 (2003) 134-143
11. Kennedy J.S., Zagar A., Bymaster F., et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatr Psychiatry 16 Suppl 1 (2001) S24-S32
12. Street J.S., Clark W.S., Gannon K.S., et al., HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A doubleblind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57 (2000) 968-976
13. Ballard C., Margallo-Lana M., Juszczak E., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ 330 (2005) 874
14. [WMA Web site]. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Accessed March 15, 2006 (1989), WMA, Ferney Voltaire, France. http://www.wma.net Accessed March 15, 2006
15. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
16. [CONSORT Web site]. Available at:. Moher D., Schulz K.F., Altman D.G., and CONSORT Group. CONSORT Statement: Revised recommendations for improving the quality of reports of parallel group randomized trials 2001. Accessed March 15 (2006). http://www.consort-statement.org/Statement/revisedstatement.htm#flow
17. Hope T., Keene J., Fairburn C.G., et al. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br J Psychiatry 174 (1999) 39-44
18. Lloyd C., Hafner R.J., and Holme G. Behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 8 (1995) 213-216
19. Mendiondo M.S., Ashford J.W., Kryscio R.J., and Schmitt F.A. Modelling Mini Mental State Examination changes in Alzheimer's disease. Stat Med 19 (2000) 1607-1616
20. Morris J.C., Edland S., Clark C., et al. The consortium to establish a registry forAlzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 43 (1993) 2457-2465
21. (Suppl). Heyman A., Fillenbaum G., and Nasa F. Consortium to Establish a Registry for Alzheimer's Disease: The CERAD Experience. Neurology 49 (1997) S1-S23
22. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
23. Scharre D.W., and Chang S.I. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 16 (2002) 128-130
24. De Deyn P.P., Carrasco M.M., Deberdt W., et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patientswith Alzheimer's disease. Int J Geriatr Psychiatry 19 (2004) 115-126